Claude Maraoui Sells 14,905 Shares of Journey Medical Co. (NASDAQ:DERM) Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 14,905 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.01, for a total value of $74,674.05. Following the completion of the sale, the chief executive officer now owns 2,052,418 shares of the company’s stock, valued at approximately $10,282,614.18. This trade represents a 0.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Claude Maraoui also recently made the following trade(s):

• On Tuesday, March 11th, Claude Maraoui sold 49,271 shares of Journey Medical stock. The shares were sold at an average price of $5.01, for a total value of $246,847.71.
• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total value of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Stock Up 3.0 %

DERM stock opened at $5.15 on Wednesday. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market capitalization of $107.58 million, a P/E ratio of -5.48 and a beta of 0.97. Journey Medical Co. has a 52-week low of $2.85 and a 52-week high of $6.89. The company’s 50 day simple moving average is $4.62 and its 200-day simple moving average is $5.09.

Institutional Trading of Journey Medical

Several large investors have recently added to or reduced their stakes in DERM. Nwam LLC acquired a new stake in shares of Journey Medical in the third quarter worth $59,000. Kovitz Investment Group Partners LLC purchased a new stake in Journey Medical in the 3rd quarter worth about $66,000. Geode Capital Management LLC boosted its position in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after acquiring an additional 12,882 shares during the period. PVG Asset Management Corp grew its stake in Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after acquiring an additional 9,005 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Journey Medical in the 4th quarter valued at about $80,000. 7.25% of the stock is owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.